These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 20038763

  • 1. Emerging multiple sclerosis oral therapies.
    Rammohan KW, Shoemaker J.
    Neurology; 2010 Jan 05; 74 Suppl 1():S47-53. PubMed ID: 20038763
    [Abstract] [Full Text] [Related]

  • 2. Treatment options for multiple sclerosis: current and emerging therapies.
    Gawronski KM, Rainka MM, Patel MJ, Gengo FM.
    Pharmacotherapy; 2010 Sep 05; 30(9):916-27. PubMed ID: 20795847
    [Abstract] [Full Text] [Related]

  • 3. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 05; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 4. Oral laquinimod therapy in relapsing multiple sclerosis.
    Preiningerova J.
    Expert Opin Investig Drugs; 2009 Jul 05; 18(7):985-9. PubMed ID: 19527103
    [Abstract] [Full Text] [Related]

  • 5. New oral drugs for multiple sclerosis.
    Gasperini C, Ruggieri S.
    Neurol Sci; 2009 Oct 05; 30 Suppl 2():S179-83. PubMed ID: 19882371
    [Abstract] [Full Text] [Related]

  • 6. Oral laquinimod treatment in multiple sclerosis.
    Fernández O.
    Neurologia; 2011 Mar 05; 26(2):111-7. PubMed ID: 21163185
    [Abstract] [Full Text] [Related]

  • 7. Emerging oral agents for multiple sclerosis.
    Fox EJ.
    Am J Manag Care; 2010 Sep 05; 16(8 Suppl):S219-26. PubMed ID: 20873946
    [Abstract] [Full Text] [Related]

  • 8. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
    Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, Laquinimod in Relapsing MS Study Group.
    Neurology; 2005 Mar 22; 64(6):987-91. PubMed ID: 15781813
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy of multiple sclerosis--current practice and future directions.
    Tullman MJ, Lublin FD, Miller AE.
    J Rehabil Res Dev; 2002 Mar 22; 39(2):273-85. PubMed ID: 12051470
    [Abstract] [Full Text] [Related]

  • 10. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
    O'Connor P, Comi G, Montalban X, Antel J, Radue EW, de Vera A, Pohlmann H, Kappos L, FTY720 D2201 Study Group.
    Neurology; 2009 Jan 06; 72(1):73-9. PubMed ID: 19122034
    [Abstract] [Full Text] [Related]

  • 11. Teriflunomide for oral therapy in multiple sclerosis.
    Papadopoulou A, Kappos L, Sprenger T.
    Expert Rev Clin Pharmacol; 2012 Nov 06; 5(6):617-28. PubMed ID: 23234322
    [Abstract] [Full Text] [Related]

  • 12. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
    Hecht B.
    Med Monatsschr Pharm; 2010 Apr 06; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
    [Abstract] [Full Text] [Related]

  • 13. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L.
    Lancet Neurol; 2020 Apr 06; 19(4):336-347. PubMed ID: 32059809
    [Abstract] [Full Text] [Related]

  • 14. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B, Hartung HP.
    Ann Neurol; 2007 Oct 06; 62(4):314-26. PubMed ID: 17969020
    [Abstract] [Full Text] [Related]

  • 15. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J, Kalinowska-Łyszczarz A.
    J Neuroimmunol; 2011 Feb 06; 231(1-2):15-22. PubMed ID: 20947176
    [Abstract] [Full Text] [Related]

  • 16. Multiple sclerosis therapeutic pipeline: opportunities and challenges.
    Krieger S.
    Mt Sinai J Med; 2011 Feb 06; 78(2):192-206. PubMed ID: 21425264
    [Abstract] [Full Text] [Related]

  • 17. Daclizumab treatment for multiple sclerosis.
    Kim SE.
    Pharmacotherapy; 2009 Feb 06; 29(2):227-35. PubMed ID: 19170591
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
    Neurology; 2006 Mar 28; 66(6):894-900. PubMed ID: 16567708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.